{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:17:11Z","timestamp":1759540631013},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["NA","NA","NA","NA","NA","NA","NA","NA","NA","NA"],"award-info":[{"award-number":["NA","NA","NA","NA","NA","NA","NA","NA","NA","NA"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41416-019-0530-6","type":"journal-article","created":{"date-parts":[[2019,7,28]],"date-time":"2019-07-28T23:02:36Z","timestamp":1564354956000},"page":"417-420","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma"],"prefix":"10.1038","volume":"121","author":[{"given":"Jason","family":"Chesney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Puzanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Collichio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed M.","family":"Milhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice M.","family":"Mehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,29]]},"reference":[{"key":"530_CR1","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbe, C. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"530_CR2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020\u20131030 (2014).","journal-title":"J. Clin. Oncol."},{"key":"530_CR3","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi, F. S., Hwu, W. J., Kefford, R., Weber, J. S., Daud, A., Hamid, O. et al. Evaluation of immune-related response criteria and RECISTv1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34, 1510\u20131517 (2016).","journal-title":"J. Clin. Oncol."},{"key":"530_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"530_CR5","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka, R. H., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K. A. et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann. Surg. Oncol. 23, 4169\u20134177 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"530_CR6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119 (2017).","journal-title":"Cell"},{"key":"530_CR7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36, 1658\u20131667 (2018).","journal-title":"J. Clin. Oncol."},{"key":"530_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0530-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0530-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0530-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:26Z","timestamp":1684616726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0530-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0530-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,29]]},"assertion":[{"value":"16 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C. has received honoraria, consulting and\/or advisory fees, and travel and accommodations expenses from Amgen; research funding from Amgen, Iovance, and Bristol-Myers Squibb; and has received reimbursement for service on a scientific advisory panel for Replimune. I.P. has received honoraria, consulting and\/or advisory fees, and travel and accommodations expenses from Amgen. F.C. has received consulting fees from Amgen through a consulting agreement that ended in 2018, and institutional research funding from Amgen and Novartis. M.M. has served on the GIST advisory board for Blueprint Solutions and on an advisory board for Amgen. A.H. has received research funding, consulting fees, and honoraria from Novartis, Amgen, Bristol-Myers Squibb, MSD\/Merck, Pierre Fabre, Provectus, and Roche; research funding and consulting fees from Merck Serono, Philogen, and Regeneron; consulting fees and speakers\u2019 honoraria from Sanofi-Aventis, and consulting fees from OncoSec and Philogen. L.C. and A.S. are employees of and own stock in Amgen. C.G. has received honoraria and consulting and\/or advisory fees from Amgen, Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, and Roche; research funding from Bristol-Myers Squibb, Novartis, and Roche; and travel and accommodations expenses from Amgen, Bristol-Myers Squibb, Merck Sharpe & Dohme, and Novartis. P.S. has nothing to disclose. J.M. has received honoraria and consulting and\/or advisory fees from Boehringer Ingelheim, EMD Serono, Pfizer, Merck, and Amgen; research funding from Amgen, Novartis, Merck, Polynoma, AstraZeneca, Immunocore, Macrogenics, and Incyte; and travel and accommodation expenses from Merck, EMD Serono, and Boehringer Ingelheim.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients provided written informed consent; study procedures were approved by the institutional review boards\/ethics committees at each site (for a listing of the names for all participating sites see Table S3). The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study was sponsored by Amgen Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Patient consent was obtained for all images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Qualified researchers may request data from Amgen clinical studies. Complete details are available at the following: ExternalRef removed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}